PacBio, Lucid Genomics announces collaboration to advance tertiary analysis

PacBio (PACB) and Lucid Genomics announced that Lucid Genomics has joined the PacBio Compatible partner program as a solution for tertiary analysis of data generated on PacBio long-read sequencing instruments. “Being recognized as a PacBio Compatible partner is a significant milestone for Lucid Genomics and for our customers. Long-read sequencing is unlocking parts of the genome that were simply invisible before: non-coding regions, methylation patterns, structural variants in the dark genome,” said Dr. Uira Souto Melo, Founder & CEO, Lucid Genomics. “Lucid was built from the ground up as a long-read native company to extract exactly this kind of diagnostic value. This designation gives our users confidence they are working with a solution that is tested, trusted, and purpose-fit for PacBio sequencing.”